Increasing APP proteolytic processing based on gene therapy, transcriptional activation or even pharmacological activation of APP-degrading enzymes has represented a novel therapeutic strategy for the treatment of AD, which is currently being evaluated in cell-culture and animal models [13–15]. Here, APP is linked to Alzheimer disease.